RxDoctor Payments Data

Theresa Putman

Nurse Practitioner · Reform, ALNPI 1609114198

Payments from drug & device makers

$2,566in general payments, 2019–2025

Across 130 payments — averaging $19.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$509
  • Otsuka America Pharmaceutical, Inc.$436
  • Bayer$211
  • Vanda Pharmaceuticals Inc.$204
  • Novo Nordisk$152
  • Astellas Pharma US Inc$90
  • plus $964 from 24 others

What the payments were for

  • Food & beverage$2,566100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,566 in reported general payments places this provider in the 80th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$104,342
Medicare patients
245
Services billed
1,883

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine19$99,467
RexultiBrexpiprazole27$38,843
OzempicSemaglutide26$26,583
EliquisApixaban31$21,370
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$19,149
JardianceEmpagliflozin20$15,834
JanuviaSitagliptin Phosphate19$15,025
XareltoRivaroxaban22$14,329
VascepaIcosapent Ethyl12$8,316
MyrbetriqMirabegron12$7,994
LinzessLinaclotide13$7,991
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl42$7,671
AbrysvoRsv Vacc, Pref A And Pref B/Pf14$4,426
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen193$3,304
Gabapentin239$3,202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$40$99,46719 claims
Otsuka America Pharmaceutical, Inc.Rexulti$436$38,84327 claims
Novo NordiskOzempic$152$26,58326 claims
PfizerEliquis, Abrysvo$47$25,79645 claims
GSKTrelegy Ellipta$21$19,14928 claims
Boehringer IngelheimJardiance$17$15,83420 claims
Astellas Pharma US IncMyrbetriq$90$7,99412 claims
AbbVieLinzess$509$7,99113 claims
Scilex Pharmaceuticals Inc.Colchicine$45$73614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Reform

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →